Lyophilized monoclonal antibody (mAb) encoded mRNA—lipid nanoparticles (LNPs) lead to stable in vivo expression of mAb after room temperature storage
Authors:
- Zimeng WangZWZimeng Wang
- Bei ChengBCBei Cheng
- Christine TkaczykCTChristine Tkaczyk
- Michael NewtonMNMichael Newton
- Shuolin CuiSCShuolin Cui
- Bohdan AndreiukBABohdan Andreiuk
- Sanjib SahaSSSanjib Saha
- Sabrina KhanSKSabrina Khan
- Charles ChenCCCharles Chen
- Bin YangBYBin Yang
- Adam GamsonAGAdam Gamson
- Sarah SiddiquiSSSarah Siddiqui
Open Access
- 23 March 2026
- journal article
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Abstract
The recent success of mRNA COVID-19 vaccines using lipid nanoparticles (LNPs) underscores the potential of this technology for delivering gene-encoded biologics in humans. Passive immunization by in vivo expression of monoclonal antibodies (mAbs) could provide advantages over traditional vaccines due to its immediate protection and broader applicability. The use of mRNA allows for rapid development and easily scalable production, while in vivo expression of biologics (IVEB) reduces the complexity and cost associated with traditional mAb manufacturing by leveraging the body as a bioreactor. However, the requirement of cold chain storage and transportation remains a critical challenge for the distribution of mRNA-LNP formulations. Lyophilization of the mRNA-LNP formulations to produce dry powder offers a potential solution to this issue. In this study, we have investigated several lyophilization conditions for mRNA-LNP and evaluated their efficacy both in vitro and in vivo . Further physical stability and structure characterization provided insights into the structure-efficacy relationship. We successfully identified the lyophilization condition using 5 mM Tris buffer at pH 8 with 10% sucrose, which retained LNP particle size within an acceptable range, preserved mRNA encapsulation efficiency, and maintained consistent level of in vivo expressed mAbs after being stored at room temperature for a month.Keywords
Funding Information
- Defense Advanced Research Projects Agency (HR011-18-3-001)
This publication has 42 references indexed in Scilit:
- Formulation screening of lyophilized mRNA-lipid nanoparticlesInternational Journal of Pharmaceutics, 2025
- Inhalable Dry Powders for Lung mRNA DeliveryAdvanced Healthcare Materials, 2024
- Stable and inhalable powder formulation of mRNA-LNPs using pH-modified spray-freeze dryingInternational Journal of Pharmaceutics, 2024
- Design and lyophilization of mRNA-encapsulating lipid nanoparticlesInternational Journal of Pharmaceutics, 2024
- Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and dryingInternational Journal of Pharmaceutics, 2023
- Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary deliveryDrug Delivery and Translational Research, 2023
- Investigating freezing-induced acidity changes in citrate buffersInternational Journal of Pharmaceutics, 2023
- Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection PotencyAdvanced Materials, 2023
- The Effect of Cryoprotectants and Storage Conditions on the Transfection Efficiency, Stability, and Safety of Lipid‐Based Nanoparticles for mRNA and DNA DeliveryAdvanced Healthcare Materials, 2023
- Assessing the effects of solid versus liquid dosage forms of oral medications on adherence and acceptability in childrenCochrane Database of Systematic Reviews, 2017